Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine-Reference-Cited by-同舟云学术

Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine

Published:2017-12 Issue:8 Volume:28 Page:670-680
ISSN:0955-8810
Container-title:Behavioural Pharmacology
language:en
Short-container-title:

Author:

Ando Kiyoshi,Nishime Chiyoko,Inoue Ryo,Nishinaka Eiko,Kawai Kenji,Urano Koji,Tsutsumi Hideki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Psychiatry and Mental health,Pharmacology

Reference26 articles.

1. Effects of l-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats;Abercrombie;Brain Res,1990

2. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets;Ando;Psychopharmacology (Berl),2008

3. PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson’s disease;Ando;PloS One,2012

4. l-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson’s disease model;Ando;Pharmacol Biochem Behav,2014

5. A functional assessment of embryonic dopaminergic grafts in the marmoset;Annett;Prog Brain Res,1990

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a new 3D tracking system for multiple marmosets under free-moving conditions;2022-10-04

2. Development of a new 3D tracking system for multiple marmosets under free-moving conditions;2022-03-30

3. The common marmoset in biomedical research: experimental disease models and veterinary management;Experimental Animals;2022

4. Classic and evolving animal models in Parkinson's disease;Pharmacology Biochemistry and Behavior;2020-12

5. Measurement of baseline locomotion and other behavioral traits in a common marmoset model of Parkinson's disease established by a single administration regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: providing reference data for efficacious preclinical evaluations;Behavioural Pharmacology;2020-02